Medexus Pharmaceuticals Inc. reports news on its specialty pharmaceutical portfolio and North American commercial operations. The company's updates center on GRAFAPEX (treosulfan) for Injection in the United States, financial results, and product-level trends across therapeutic areas that include hematology and hematology-oncology, rheumatology, allergy, and dermatology.
Medexus news also covers capital allocation and capital structure actions, including credit facilities, warrant expirations, and normal course issuer bid activity, along with shareholder meeting results, conference calls, and management participation in investor conferences.
Medexus Pharmaceuticals announced its upcoming presentation at the virtual Winter Wonderland Conference, hosted by The MicroCap Rodeo, from February 16-19, 2021. CEO Ken d’Entremont and CFO Roland Boivin will present on February 17 at 9:30 AM ET, with the session available for live streaming and replay. Medexus is recognized for its innovative products in treating rare diseases, specializing in auto-immune diseases, hematology, and allergies. Key products include Rasuvo™, Metoject®, IXINITY®, and Rupall®.
Medexus Pharmaceuticals (OTCQX: MEDXF) will present at the LD 500 Investor conference virtually from September 1-4, 2020. CEO Ken d'Entremont and CFO Roland Boivin are scheduled to speak on September 1 at 11:40 a.m. ET, with a live webcast available.
Attendees can schedule one-on-one video meetings and register for the event online. Medexus specializes in healthcare products for auto-immune diseases, hematology, and allergy treatments, with notable products including Rasuvo™, IXINITY®, and Rupall®.